A Degarelix Trial in Patients With Prostate Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.

DRUG

Goserelin acetate

The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.

Trial Locations (63)

Unknown

University of Colorado School of Medicine, Aurora

The Urology Center of Colorado, Denver

Urology Associates of Dover, PA, Dover

South Florida Medical Research, Aventura

Urology Group of New Mexico, PC, Albuquerque

Carolina Urologic Research Center, Myrtle Beach

Urology San Antonio Research, Pa, San Antonio

Seattle Urology Research Center, Burien

AZ Groeninge - Campus Sint-Maarten, Kortrijk

Jonathan Giddens Medicine Professional Corporation, Brampton

Southern Interior Medical Research Inc., Kelowna

Mor Urology, Inc., Newmarket

Investigational site, Scarborough

Investigational site, Toronto

Urocentrum Brno, Brno

Nemocnice Jindrichuv Hradec, a.s., Jindřichův Hradec

Kromerizska nemocnice a.s., Kroměříž

Fakultni nemocnice v Motole, Praha 5, Prague

Vseobecna fakultni nemocnice v Praze, Praha 2, Prague

Krajska nemocnice T. Bati a.s., Zlín

ODL Terveys Oy, Oulu

Pohjois-Karjalan keskussairaala, Tampere

Tampereen yliopistollinen sairaala, Tampere

Gemeinschaftspraxis Rudolph & Wörner, Kirchheim

Urologische Studienpraxis, Nürtingen

Fövárosi Önkormányzat Bajcsy-Zsilinszky Kórház, Budapest

Fövárosi Önkormányzat uzsoki utcai Kórház, Budapest

Semmelweis Egyetem, Budapest

Dombóvári Szent Lukács Egészségügyi Nonprofit Kft., Dombóvár

Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Miskolc

Miskolci Semmelweis Ignác Egészségügyi Központ és Egyetemi Oktató Kórház Nonprofit Kft, Miskolc

Pécsi Tudományegyetem, Pécs

Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ, Szeged

Jávorszky Ödön Kórház, Vác

Hospital Christus Muguerza del Parque, Chihuahua, Chih.

Hospital Angeles Culiacan, Culiacan, Sinaloa

Consultorio de Especialidad en Urologia Privado, Durango

Médica Sur, S.A.B. de C.V., Mexico City

Hospital Angeles Lindavista, Mexico City, DF

Consultorio Medico, Zapopan, Jalisco

Catharina-ziekenhuis, Eindhoven

MC Haaglanden, The Hague

SPZOZ Wojewodzki Szpital Zespolony im. J.Sniadeckiego, Bialystok

Centrum Medyczne Medur Sp. z o.o., Bielsko-Biala

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku, Słupsk

Private Medical Center SRL, Arad

Brasov Emergency Clinical County Hospital, Brasov

"Prof. Dr. Th. Burghele Clinical Hospital", Bucharest

"Sfantul Ioan Emergency Clinical Hospital", Bucharest

Dinu Uromedica, Bucharest

Fundeni Clinical Institute of Uronephrology and Renal Transplantation, Bucharest

PROVITA 2000 Medical Center, Constanța

"Dr. C.I. Parhon Clinical Hospital", Iași

Vita Care Flav Medical Center, Piteşti

Sibiu Emergency Clinical County Hospital, Sibiu

Dnipropetrovsk State Medical Academy, Dnipropetrovsk

Donetsk Regional Clinical Territorial Medical Association, Donetsk

Regional Clinical Center of Urology and Nephrology n.a. V.I.Shapoval, Kharkiv

Kyiv City Clinical Hospital #3, Kyiv

Odesa Regional Clinical Hospital, Odesa

"Municipal Institution Zaporizhzhia Regional Clinical Hospital", Zaporizhzhya

Ipswich Hospital, Ipswich

The Royal Marsden NHS Foundation Trust, Sutton

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT01242748 - A Degarelix Trial in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter